Abstract:Abstract Development of new drugs is of high interest for the field of cardiac and cardiovascular diseases, which are a dominant cause of death worldwide. Before being allowed to be used and distributed, every new potentially therapeutic compound must be strictly validated during preclinical and clinical trials. The preclinical studies usually involve the in vitro and in vivo evaluation. Due to the increasing reporting of discrepancy in drug effects in animal and humans and the requirement to reduce the number of animals used in research, improvement of in vitro models based on human cells is indispensable. Primary cardiac cells are difficult to access and maintain in cell culture for extensive experiments; therefore, the human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) became an excellent alternative. This technology enables a production of high number of patient- and disease-specific cardiomyocytes and other cardiac cell types for a large-scale research. The drug effects can be extensively evaluated in the context of electrophysiological responses with a use of well-established tools, such as multielectrode array (MEA), patch clamp, or calcium ion oscillation measurements. Cardiotoxicity, which is a common reason for withdrawing drugs from marketing or rejection at final stages of clinical trials, can be easily verified with a use of hiPSC-CM model providing a prediction of human-specific responses and higher safety of clinical trials involving patient cohort. Abovementioned studies can be performed using two-dimensional cell culture providing a high-throughput and relatively lower costs. On the other hand, more complex structures, such as engineered heart tissue, organoids, or spheroids, frequently applied as co-culture systems, represent more physiological conditions and higher maturation rate of hiPSC-derived cells. Furthermore, heart-on-a-chip technology has recently become an increasingly popular tool, as it implements controllable culture conditions, application of various stimulations and continuous parameters read-out. This paper is an overview of possible use of cardiomyocytes and other cardiac cell types derived from hiPSC as in vitro models of heart in drug research area prepared on the basis of latest scientific reports and providing thorough discussion regarding their advantages and limitations.

Ultrathin and Flexible Bioelectronic Arrays for Functional Measurement of iPSC-Cardiomyocytes under Cardiotropic Drug Administration and Controlled Microenvironments

In Vitro Assessing the Risk of Drug-Induced Cardiotoxicity by Embryonic Stem Cell-Based Biosensor

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Integrated Cell-Based Biosensor for Extracellular Electrophysiological Monitoring

Design and fabrication of an integrated heart-on-a-chip platform for construction of cardiac tissue from human iPSC-derived cardiomyocytes and in situ evaluation of physiological function

Multifunctional cardiac microphysiological system based on transparent ITO electrodes for simultaneous optical measurement and electrical signal monitoring

Biomimetic Cardiac Microsystems for Pathophysiological Studies and Drug Screens

Flexible 3D printed microwires and 3D microelectrodes for heart-on-a-chip engineering

Establishment of a heart-on-a-chip microdevice based on human iPS cells for the evaluation of human heart tissue function

Simultaneous electromechanical monitoring in engineered heart tissues using a mesoscale framework

Continuous Contractile Force and Electrical Signal Recordings of 3D Cardiac Tissue Utilizing Conductive Hydrogel Pillars on a Chip

Ultrasoft electronics to monitor dynamically pulsing cardiomyocytes

Micro‐Engineered Heart Tissues on‐Chip with Heterotypic Cell Composition Display Self‐Organization and Improved Cardiac Function

Engineering Cardiac Tissue for Advanced Heart‐on‐a‐chip Platforms

Synchronized High-Content Recording of Cardiomyocytes in Vitro by Integrated Cell-Based Biosensor

Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research

A Platform for Generation of Chamber-Specific Cardiac Tissues and Disease Modeling

Heart-on-a-Chip Model with Integrated Extra- and Intracellular Bioelectronics for Monitoring Cardiac Electrophysiology under Acute Hypoxia

Integrated Microdevice for Long-Term Automated Perfusion Culture Without Shear Stress and Real-Time Electrochemical Monitoring of Cells.

A microscale biomimetic platform for generation and electro-mechanical stimulation of 3D cardiac microtissues

Heart-on-a-chip systems with tissue-specific functionalities for physiological, pathological, and pharmacological studies